RAPS Convergence 2025 Success! Driving Regulatory and Medical Authoring into the Future!
Oct 09, 2025π What a dynamic week at RAPS Convergence 2025 in Pittsburgh! From groundbreaking AI-powered authoring to deep dives into regulatory modernization, the momentum was real β and the potential, game-changing. π‘ Hereβs a glimpse into how industry leaders are rewriting the rulebook on document workflows, accelerating timelines, and embracing the future of regulatory & medical writing.
What a productive and insightful week at RAPS Convergence 2025 in Pittsburgh, PA (October 7β9)! We were thrilled to engage with the global community of regulatory affairs professionals and leaders from pharma, biotech, medical devices, and CROs.
A huge congratulations to our Founder and CEO, Sharon Chen, for her highly impactful presentation, "How Leading Global Pharma Embraces AI to Automate Regulatory and Medical Documents with Quality Control," on October 8th! ποΈ
The session highlighted how global pharmaceutical leaders are modernizing regulatory and medical writing by adopting AI-driven platforms. These platforms generate critical documents like protocols, Clinical Study Reports (CSRs), and Investigator Brochures (IBs), while ensuring rigorous quality control and traceability.
Our discussions focused heavily on the transformative value that AI automation brings to the regulatory lifecycle:
Accelerated Time to Market: Generative AI is capable of cutting CSR timelines from 8β14 weeks down to 5β8 weeks, supporting a confirmed 30β50% reduction in overall document cycle time.
Significant Financial Impact: For Top 20 Pharma companies, this acceleration translates to potential ~$1.4 billion in Revenue Acceleration, equating to approximately 3.5% in annual revenue growth.
The Power of Automation: The AI automation process fundamentally changes content generation from a manual, linear workflow to one powered by AI. The process shifts from "Manual Draft" to "AI Draft" with integrated "AI QC" before human review and publishing.
Comprehensive Document Support: AuroraPrime supports AI-driven content automation across the full drug development spectrum (Pre-Clinical, Clinical, Submission, and Post-Market). Documents with high automation value include CSRs, Protocols, Patient Safety Narratives, Clinical Overviews (M2.5), and PBRER.
Built-in Efficiency: The AuroraPrime platform utilizes capabilities such as RAG-based Knowledge retrieval, Multi-Lingual Support, and Table-to-Text/Text-to-Table conversion. It ensures continuous efficiency by automating the entire document lifecycle, including draft, review, update, and quality check phases.
Attendees learned how the AuroraPrime RMA solution is setting new benchmarks in efficiency and compliance. AuroraPrime RMA, a purpose-built, GenAI-powered SaaS solution, is designed to transform the creation of clinical documentation. It's trusted by over half of the Top-20 Global Pharma companies, and helps achieve real results, such as up to a 90% reduction in first draft time for documents like CSRs and Protocols.
We extend our deep gratitude to everyone who attended Sharonβs insightful session and visited us at Booth 411! Your engagement reinforces our commitment to accelerating R&D cycles through AI excellence.
Ready to explore how the AuroraPrime RMA solution can streamline your end-to-end compliance workflows and expedite regulatory document development? π‘ Connect with AlphaLife Sciences today: π https://alphalifesci.com/events/raps-convergence-2025
